Monday, September 28, 2009

Moving Rapidly from Target Discovery to Lead Development: RNAi in the Context of the Emerging Drug Development Paradigm (Journal Club)

That RNAi is now widely employed in the Pharma world for target identification and validation purposes is no longer a secret. That RNAi may immediately lend itself as the therapeutic agent as well has been recognized by Merck, Novartis, and Roche, and it is this widespread familiarity with the technology that is also a major driver for more Big Pharma companies embracing RNAi as a therapeutic platform technology, too.

Today, I’d like to use a paper by Dan Cao on the identification of new host factors for Hepatitis Delta Virus (HDV) replication to illustrate how easy it is now, in theory, to exploit RNAi to dramatically shorten drug development timelines, especially in an environment that demands the rapid development of drugs based on new, innovative targets (Dan et al.: Combined proteomic-RNAi screen for host factors involved in human hepatitis delta virus replication. RNA [epub ahead of print]).

HDV is typically found in the context of a Hepatitis B Virus (HBV) infection as HDV requires HBV to introduce its genetic material into the host cell. Viral replication, however, is independent of HBV, and there are indeed a few patients that have got rid of HBV, but still harbor HDV. While this is uncomfortable already, having both active HBV and HDV is not pleasant at all. Because HDV is a condition thought to be of little pharmaco-economic importance, there is no HDV-specific drug. The identification of viral host factors therefore would immediately yield candidates for the development of RNAi-based drugs specific for HDV, in addition to the basic molecular biology insight they might provide for the study of RNA-directed transcription for which HDV is a great model system.

Targeting host factors is especially attractive for RNA viral infections, because it should be much more difficult for the virus to escape the drug by mutation. There are a number of well-publicized studies identifying host factors for HIV through genome-wide RNAi screens. This, however, demands a dedicated RNAi screening facility and a lot of hard work. Moreover, relying on just one technology, albeit RNAi, should increase false negatives, and especially false positives. The alternative approach would be to search the literature for reported viral host factors and then target such a list of genes by RNAi. The draw-back of this approach is that it will not include new factors and that the quality of reported factors can be quite ‘variable’.

For all these reasons, but particularly because the life-span and budget of a post-doc are limited, Dan decided to take a slightly different tack. The approach relies on employing two functionally independent screens for HDV host factors, but which because they were serially coupled should increase the quality of the identified factors while reducing the overall workload.

In a first screen for HDV-related host factors, the only viral protein (HDAg) was immunoprecipitated and associated proteins identified by mass-spectrometry. Over 100 proteins were such identified, although some were more and some less abundant. Among the most abundant ones were several subunits of the host RNA Polymerase II complex, which carries out viral replication and this therefore was a great validation for the validity of the immunoprecipitation results. The proteome-wide IP-mass spectrometry was relatively painless since the IP eluate could be handed over to the mass-spec core facility almost unprocessed and was then analyzed by a skilled specialist using standard methods (about one week, i.e. negligible turnaround for somebody that has gone through the process once).

Dan then picked about 60 genes from the list and got about 3 siRNAs for each. These were used in a screen for their ability to inhibit HDV replication. Although this still requires hard labor, 60 is a number that is within the reach of a single worker and no complicated screening facility is required. All you basically need is a good screen. Thanks to the existence of genome-wide siRNA libraries (which, of course, is a result of the interest in RNAi), the cost of siRNAs has also come down dramatically compared to 5 to 7 years ago (from $250 an siRNA to about $15-20 an siRNA). In summary, ~1 ½ man years identified about 5-10 genes that both interacted with HDAg and when knocked down strongly inhibited HDV replication.

Although not done in this study, these candidates could now be vetted in the literature for whether they may make for good targets (based on predicted requirement for cell viability etc), and then tested in small animal models of HDV infection for pre-clinical in vivo proof-of-concept using existing siRNA delivery technologies for the liver. After another 2 years of siRNA chemistry and pre-clinical pharm/tox (which will be routine in a company with an established RNAi Therapeutic platform) you could imagine to be in the clinic.

This is just a small example of how RNAi may be ideally suited as a therapeutic modality in an age of personalized medicines where pharmaco-economic principles would demand efficient drug development. An article mentioning GSK’s intention to announce next month an orphan-disease initiative is another sign of the times, and gets me a little bit more excited about Alnylam’s prospects for a platform deal- maybe even this year (see also blog on the neglected disease patent pool donation). Who knows, one day it may not just be the government of Taiwan that is interested in treating HDV anymore.


Abstract:

Combined proteomic-RNAi screen for host factors involved in human hepatitis delta virus replication.

Cao D, Haussecker D, Huang Y, Kay MA.

Department of Pediatrics, Stanford University, Stanford, California 94305-5164, USA.

Human hepatitis delta virus (HDV) is the only animal virus known to replicate its RNA genome using a host polymerase because its only virally encoded proteins, the small and large hepatitis delta antigens (HDAg-S and HDAg-L), lack polymerase activity. Although this makes HDV an ideal model system to study RNA-directed transcription in mammalian cells, little is known about the host factors involved in its replication. To comprehensively identify such host factors, we created a stable cell line carrying a functional FLAG-HDAg-S. Anti-Flag immunopurification and mass spectrometry identified >100 proteins associated with FLAG-HDAg-S, many of which had predicted roles in RNA metabolism. The biological relevance of this screen was strongly supported by the identification of nine out of the 12 subunits of the RNA polymerase II complex thought to mediate HDV replication. To further investigate the significance of these factors for HDV replication, we selected 65 proteins to look for factors that would also affect the accumulation of HDV RNA following siRNA knockdown. Fifteen and three factors were found to regulate HDV RNA accumulation negatively and positively, respectively, upon RNAi knockdown. Our results provide a valuable resource for future research to advance our mechanistic understanding of HDV replication and RNA-directed transcription in mammalian cells.

No comments:

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.